Purinostat Mesylate
甲磺酸普依司他
Purinostat Mesylate (PM) is a highly selective HDAC inhibitor developed by Zenitar (赜灵生物) as its core product . It is the first in the world to enter clinical trials as a single-agent therapy for relapsed/refractory lymphoma . The drug is among Zenitar's clinical pipeline candidates, which also include ZL-82, FM, and ZL-85FA . Zenitar raised nearly RMB 400 million in a Series B+ round in August 2025, with participation from Qiming Venture Partners, Gaorong Ventures, and 5Y Capital .
AI-generated — may contain errors, please verify.
Coverage
5Y News | Zai Ling Bio Completes Nearly RMB 400 Million Series B+ Round
Accelerating the buildout of an innovative drug pipeline built on differentiated molecular scaffolds and novel targets, with a commitment to addressing unmet clinical needs.
Zenitar Closes Nearly RMB 400 Million Series B+ Round, Multiple Global First-in-Class Drugs Enter Pivotal Clinical Trials
Structural Biology and AI-Driven Innovative Drug Discovery and Development
Zenitar Raises Nearly 400 Million Yuan in B+ Round Led by Qiming Venture Partners
Zenitar is a structure-based biology and AI-driven innovative drug R&D company, focused on unmet clinical needs in major therapeutic areas including oncology, autoimmune diseases, inflammation, and neurological disorders. The company is dedicated to discovering, developing, and commercializing first-in-class and best-in-class innovative medicines.
